Company Profile

ALEMBIC PHARMACEUTICALS LTD.

NSE : APLLTDBSE : 533573ISIN CODE : INE901L01018Industry : Pharmaceuticals & DrugsHouse : Alembic
BSE926.0010.35 (+1.13 % )
PREV CLOSE (Rs.) 915.65
OPEN PRICE (Rs.) 899.00
BID PRICE (QTY) 927.50 (3 )
OFFER PRICE (QTY) 928.60 (10 )
VOLUME 19812
TODAY'S LOW / HIGH (Rs.)883.00 928.60
52 WK LOW / HIGH (Rs.)436.1 1128
NSE930.25 15.45 (+1.69 % )
PREV CLOSE(Rs.) 914.80
OPEN PRICE (Rs.) 908.00
BID PRICE (QTY) 930.25 (15744 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 596529
TODAY'S LOW / HIGH(Rs.) 881.00 948.00
52 WK LOW / HIGH (Rs.)434.8 1128.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 1.08
TTM EPS (Rs.) 57.63
P/E Ratio 16.07
Book Value (Rs.) 224.59
Face Value (Rs.) 2
MCap (Rs. in Mn) 182017.45
Price/Earning (TTM) 14.31
Price/Sales (TTM) 4.05
Price/Book (MRQ) 4.12
PAT Margin (%) 23.46
ROCE (%) 27.08
Incorporation Year : 2010

Management Info :

Chirayu Amin - Chairman Shaunak Amin - Managing Director

Registered Office :

Address : Alembic Road, , ,
Vadodara,
Gujarat-390003

Phone : 0265 - 2280550 , 2280880

Registrar's Details : Link Intime India Pvt Ltd.
B-102 & B103, Shangrila Complex, First Floor,Opp: HDFC Bank, Near Radhakrishna Char Rasta,Akota,Vadodara
Listing : BSE, NSE, MCX
NEWS More
07Sep09-07-2020$Alembic Pharmaceuticals’ arm gets tentative approval for Treprostinil Injection Alembic Pharmaceuticals’ a

Alembic Pharmaceuticals’ wholly owned subsidiary -- Alembic Global Holdings SA has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), Multiple-Dose Vials. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RlD), Remodulin Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10mg/ml), of United Therapeutics Corp (United).

Treprostinil Injection has an estimated market size of $ 466.1 million for twelve months ending December 2019. Alembic now has a total of 131 ANDA approvals (113 final approvals and 18 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharmaceuticals’ wholly owned subsidiary -- Alembic G..
27Aug08-27-2020$Alembic Pharmaceuticals gets USFDA’s tentative approval for Empagliflozin, Linagliptin Tablets Alembic Pharmaceuticals gets

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Empagliflozin and Linagliptin Tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and Linagliptin is appropriate.

Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg have an estimated market size of $ 244 million for twelve months ending June 2020. Alembic now has a total of 130 ANDA approvals (113 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharmaceuticals has received tentative approval from th..
27Aug08-27-2020$Alembic Pharmaceuticals zooms on getting USFDA’s tentative approval for Empagliflozin, Linagliptin Tablets Alembic Pharmaceuticals zoom

Alembic Pharmaceuticals is currently trading at Rs. 1023.60, up by 32.80 points or 3.31% from its previous closing of Rs. 990.80 on the BSE.

The scrip opened at Rs. 990.80 and has touched a high and low of Rs. 1024.45 and Rs. 990.80 respectively. So far 6687 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1128.00 on 07-Aug-2020 and a 52 week low of Rs. 436.10 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 1033.30 and Rs. 988.25 respectively. The current market cap of the company is Rs. 19674.00 crore.

The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.40% and 12.63% respectively.

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Empagliflozin and Linagliptin Tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and Linagliptin is appropriate.

Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg have an estimated market size of $ 244 million for twelve months ending June 2020. Alembic now has a total of 130 ANDA approvals (113 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharmaceuticals is currently trading at Rs. 1023.60, up..
26Aug08-26-2020$FDC, JMC Projects and Bank of Maharashtra to see some action today FDC, JMC Projects and Bank o

FDC has launched two variants of the COVID-19 drug, Favipiravir - PiFLU and Favenza - which will be used to treat mild to moderate cases of COVID-19 in India. The company’s PiFLU and Favenza is currently available across the country. It has also increased the production and availability of its brand of balanced electrolyte drink ‘Enerzal and Electral as according to ASPEN guidelines, 03 litres of fluid intake in a day (60 to 120 ml in every 30 min) helps in speedy recovery of people who are home quarantined.

JMC Projects (India) (JMC) has secured new orders of Rs 554 crore. The first order is for building project in South India totalling Rs 315 crore and another order is for factory project in Maharashtra of Rs 239 crore. These new orders will strengthen the company’s portfolio and will help it further expand its client base in the B&F market.

Consequent to the receipt of necessary approvals / permissions, Bank of Maharashtra has issued and allotted 73,60,49,601 Equity shares of Rs 10 each of Bank for cash at issue price of Rs 11.29 per share (including premium) to Government of India (President of India) aggregating to Rs 831 crore on preferential basis. With this allotment, Government of India holding has increased from 92.49% to 93.33%.

Greenko Energies has signed a memorandum of understanding (MoU) with NTPC Vidyut Vyapar Nigam, a wholly-owned subsidiary of NTPC to explore energy storage and renewable energy power supply solutions. The objective of the partnership is to explore the possibility of development of renewable energy based round-the-clock, flexible and dispatchable power supply offering based on integration of RE sources and pumped storage projects.

Power Grid Corporation has inked a Memorandum of Understanding (MoU) with the Advance Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC) for construction of 'PowerGrid OT Complex', a modular operation theatre complex in Navi Mumbai. TMC is a Cancer Research Institute under the Department of Atomic Energy, Government of India. Power Grid Corporation under its CSR initiatives is extending financial support to the tune of Rs 26.40 crore for developing this modular operation theatre complex (14 numbers). The complex will ensure a high degree of sterility to prevent infections, help in reduction of health care costs, improve outcomes and ensure treatment of more patients.

Alembic Pharmaceuticals’ joint venture (JV) Aleor Dermaceuticals (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desonide Lotion, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), DesOwen Lotion, 0.05% of Galderma Laboratories LP. Desonide Lotion is low to medium potency corticosteroids indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. 

Black Rose Industries has installed the next phase of additional capacity for the manufacture of polyacrylamide liquids and commenced commercial production at the facility. The current installed capacity of polyacrylamide liquids is 40,000 MTPA.

FDC has launched two variants of the COVID-19 drug, Favipiravir..
25Aug08-25-2020$Alembic Pharmaceuticals’ JV gets USFDA’s final nod for Desonide Lotion Alembic Pharmaceuticals’ J

Alembic Pharmaceuticals’ joint venture (JV) Aleor Dermaceuticals (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desonide Lotion, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), DesOwen Lotion, 0.05% of Galderma Laboratories LP. Desonide Lotion is low to medium potency corticosteroids indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. 

Desonide Lotion, 0.05% has an estimated market size of $7 million for twelve months ending June 2020 according to IQVIA. Alembic has a cumulative total of 129 ANDA approvals (113 final approvals and 16 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharmaceuticals’ joint venture (JV) Aleor Dermaceutic..
Financials More
Rs. in Millions
QTR Jun 20 ANNUAL 20
Net Profit3186.39694
Gross Profit 3815.7 11668
Operating Profit 423513376.5
Net Sales 12584.341325.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Advanced Enzyme (BSE)
 272.80 (19.99%)
M.Cap ( in Cr)
3046.59
Hester Biosciences (BSE)
 1744.95 (1.01%)
M.Cap ( in Cr)
1484.41
Panacea Biotec (BSE)
 196.80 (4.99%)
M.Cap ( in Cr)
1205.41
Suven Pharma (BSE)
 742.20 (0.93%)
M.Cap ( in Cr)
9446.91
Coral Laboratories (BSE)
 380.00 (1.31%)
M.Cap ( in Cr)
135.76
Shareholding Pattern More
PROMOTERS 72.97 %
MUTUAL FUNDS/UTI 4.98 %
FI/BANKS/INSURANCE 2.04 %
NON-INSTITUTION 12.63 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes